Diatrizoate Meglumine / Diatrizoate Sodium Injection Suppliers & Bulk Manufacturers
Available Forms: Injection / OralSolution
Available Strengths: 282 mg
Reference Brands: Gastrografin (USA), Urografin (India),
Category:
Contrast Agent
Diatrizoate Meglumine and Diatrizoate Sodium injection is indicated for radiographic examination of segments of the gastrointestinal tract (esophagus, stomach, proximal small intestine, and colon)
Diatrizoate Meglumine / Diatrizoate Sodium injection is available in Injection / OralSolution
and strengths such as 282 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Diatrizoate Meglumine / Diatrizoate Sodium injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Diatrizoate Meglumine / Diatrizoate Sodium injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Diatrizoate meglumine and diatrizoate sodium injection is an iodinated radiographic contrast agent widely used in diagnostic imaging procedures. It belongs to the class of ionic, high-osmolar contrast media and is designed to enhance the visibility of internal body structures during X-ray and computed tomography (CT) examinations. The presence of iodine in the formulation allows it to absorb X-rays effectively, thereby improving image contrast and helping clinicians obtain clearer and more detailed diagnostic images.
This combination is commonly used for imaging of the gastrointestinal tract, urinary system, and certain vascular studies. It may be administered orally, rectally, or via injection depending on the type of procedure and diagnostic requirement. The dual-salt formulation of diatrizoate meglumine and diatrizoate sodium helps optimize solubility and imaging performance, making it suitable for a wide range of radiographic applications.
Due to its rapid distribution and reliable contrast-enhancing properties, it has been widely used in clinical practice for many years. Although newer low-osmolar and non-ionic contrast agents are increasingly preferred in some settings, this combination remains an important and cost-effective option in many healthcare systems worldwide when used under proper medical supervision.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing